FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	OMB APPROVAL								
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* George Simeon					2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [CRSP]							(Che	elationship of the contract of	•				
(Last) (First) (Middle) C/O CRISPR THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/11/2020								Officer below)	(give title		Other (s below)	pecify	
610 MAIN STREET				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBR	IDGE M	IA	02139									2	Form f	Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	itate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,		Code (Ins	Transaction Disposed Of (D) (Instr. 3, 4) Code (Instr. 5)				5. Amour Securitie Beneficia Owned F Reported	s ally following	Form: (D) or	orm: Direct 0) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code V	Amou	nt (A	or	Price	Transact (Instr. 3 a	ion(s)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	ate, T	Code (Ins				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owne Form: Iy Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Coo					Code	v	(A)	(D)	Date Exercisable	Expiratio Date	n Title	or No of	umber					
Stock Option (Right to Buy)	\$59.7	06/11/2020			A		15,000		(1)	06/11/203	0 Comm Share		5,000	\$0.00	15,000		D	

Explanation of Responses:

1. This option was granted on June 11, 2020 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2020; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2021 Annual General Meeting of Shareholders.

Remarks:

/s/ Michael Esposito, attorney-

06/15/2020

in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.